| __timestamp | Ligand Pharmaceuticals Incorporated | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 179279000 |
| Thursday, January 1, 2015 | 5807000 | 186359000 |
| Friday, January 1, 2016 | 5571000 | 171785000 |
| Sunday, January 1, 2017 | 5366000 | 208136000 |
| Monday, January 1, 2018 | 6337000 | 198405000 |
| Tuesday, January 1, 2019 | 11347000 | 224169000 |
| Wednesday, January 1, 2020 | 30419000 | 245044000 |
| Friday, January 1, 2021 | 62176000 | 252314000 |
| Saturday, January 1, 2022 | 52827000 | 268225000 |
| Sunday, January 1, 2023 | 35049000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. Ligand Pharmaceuticals Incorporated and Taro Pharmaceutical Industries Ltd. have shown contrasting trends in their cost of revenue from 2014 to 2023. Ligand Pharmaceuticals started with a modest cost of revenue, peaking in 2021 with a 580% increase from 2014. However, by 2023, their costs had decreased by 44% from the peak, indicating a strategic shift or operational efficiency.
On the other hand, Taro Pharmaceutical Industries consistently maintained higher costs, with a steady increase of 70% over the decade. This could reflect their expansive operations or investment in growth. Notably, Taro's costs in 2023 were nearly nine times that of Ligand's, highlighting their larger scale. Missing data for Ligand in 2024 suggests a potential restructuring or reporting delay, adding intrigue to their future strategy.
Analyzing Cost of Revenue: Novartis AG and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Viatris Inc. and Taro Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Limited vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Pharming Group N.V. and Taro Pharmaceutical Industries Ltd.
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Alkermes plc and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Geron Corporation vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.